Avectas

Avectas is accelerating the future of cell therapy with a flexible, easy-to-integrate delivery platform that manufactures healthier and more functional cells for patients. Excelling at complex editing and challenging cargo delivery, the Avectas non-viral delivery platform ensures the next generation of cell therapies can be realized. The Solupore non-viral delivery system enables the next generation of cell therapies through unparalleled cell health and superior cell functionality, expanding the possibilities for complex editing and challenging cargo delivery. Easy to integrate into existing GMP processes, Solupore accelerates the translation of life-saving therapies to patients

Cell engineering,transfection,cell therapy,car-t,gene editing,gene therapy,and crispr

Avectas operates in the Biotechnology research industry.

Avectas's revenue is 11m - 100m

Avectas has 11 - 50 employees.